- Home
- CALC vs HHS Comparison
CALC vs HHS Comparison
Compare CALC & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- HHS
- Stock Information
- Founded
- CALC 2011
- HHS 1923
- Country
- CALC United States
- HHS United States
- Employees
- CALC N/A
- HHS N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- HHS Advertising
- Sector
- CALC Health Care
- HHS Consumer Discretionary
- Exchange
- CALC Nasdaq
- HHS Nasdaq
- Market Cap
- CALC 45.4M
- HHS 26.9M
- IPO Year
- CALC N/A
- HHS N/A
- Fundamental
- Price
- CALC $3.13
- HHS $2.78
- Analyst Decision
- CALC Strong Buy
- HHS
- Analyst Count
- CALC 2
- HHS 0
- Target Price
- CALC $14.50
- HHS N/A
- AVG Volume (30 Days)
- CALC 24.5K
- HHS 300.5K
- Earning Date
- CALC 11-12-2025
- HHS 11-10-2025
- Dividend Yield
- CALC N/A
- HHS N/A
- EPS Growth
- CALC N/A
- HHS N/A
- EPS
- CALC N/A
- HHS N/A
- Revenue
- CALC N/A
- HHS $166,841,000.00
- Revenue This Year
- CALC N/A
- HHS $6.54
- Revenue Next Year
- CALC N/A
- HHS N/A
- P/E Ratio
- CALC N/A
- HHS N/A
- Revenue Growth
- CALC N/A
- HHS N/A
- 52 Week Low
- CALC $1.42
- HHS $2.33
- 52 Week High
- CALC $4.26
- HHS $6.69
- Technical
- Relative Strength Index (RSI)
- CALC 48.93
- HHS 37.63
- Support Level
- CALC $2.95
- HHS $2.73
- Resistance Level
- CALC $3.19
- HHS $2.99
- Average True Range (ATR)
- CALC 0.16
- HHS 0.17
- MACD
- CALC 0.01
- HHS -0.00
- Stochastic Oscillator
- CALC 29.55
- HHS 55.21
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.